Expression of caveolin-1, caveolin-2 and caveolin-3 in thyroid cancer and stroma

Pathobiology

Volumn 79, Issue 1, 2012, Pages 1-10

  Kim, Dokyung ^a   Kim, Haeryoung ^b   Koo, Ja Seung ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Anaplastic carcinoma; Caveolin; Epithelial mesenchymal transition; Myofibroblast; Thyroid cancer

Indexed keywords

CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; VIMENTIN;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; DIFFUSE SCLEROSING VARIANT OF THYROID PAPILLARY CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; MALE; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, PAPILLARY; CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; THYROID NEOPLASMS;

EID: 84862942668     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000329472     Document Type: Article

References (41)

1. Cohen AW, Hnasko R, Schubert W, Lisanti MP: Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84:1341-1379. (Pubitemid 39287953)
2. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, Cuel-lo-Carrion FD, Gago FE, Anderson RL: Stro-mal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009; 174:2035-2043.
3. Carcangiu ML, Bianchi S: Diffuse sclerosing variant of papillary thyroid carcinoma. Clin-icopathologic study of 15 cases. Am J Surg Pathol 1989; 13: 1041-1049. (Pubitemid 20010989)
4. Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, Matsuzuka F, Matsuu-ra N, Kakudo K, Kuma K, Miyauchi A: Ca-veolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br J Cancer 2002; 86: 912-916. (Pubitemid 34271027)
5. Ito Y, Yoshida H, Tomoda C, Uruno T, Taka-mura Y, Miya A, Kobayashi K, Matsuzuka F, Nakamura Y, Kakudo K, Kuma K, Miyauchi A: Caveolin-1 and 14-3-3 σ expression in fol-licular variant of thyroid papillary carcino-ma. Pathol Res Pract 2005; 201:545-549. (Pubitemid 41363947)
6. Bissell MJ, Radisky D: Putting tumours in context. Nat Rev Cancer 2001; 1:46-54. (Pubitemid 33741880)
7. Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
8. Bhowmick NA, Neilson EG, Moses HL: Stro-mal fibroblasts in cancer initiation and pro-gression. Nature 2004; 432:332-337. (Pubitemid 39551661)
9. Mueller MM, Fusenig NE: Friends or foes -bipolar effects of the tumour stroma in can-cer. Nat Rev Cancer 2004; 4: 839-849. (Pubitemid 39472951)
10. Orimo A, Weinberg RA: Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5: 1597-1601. (Pubitemid 44285243)
11. Polyak K, Haviv I, Campbell IG: Co-evolu-tion of tumor cells and their microenviron-ment. Trends Genet 2009; 25: 30-38.
12. Lisanti MP, Scherer PE, Tang Z, Sargiacomo M: Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol 1994; 4: 231-235. (Pubitemid 24190653)
13. Lisanti MP, Tang Z, Scherer PE, Kubler E, Koleske AJ, Sargiacomo M: Caveolae, trans-membrane signalling and cellular transfor-mation. Mol Membr Biol 1995; 12:121-124.
14. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C, Eng C: Caveo-lin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid car-cinogenesis. Cancer Res 2003; 63:2864-2871. (Pubitemid 36667158)
15. Fine SW, Lisanti MP, Argani P, Li M: Caveo-lin-3 is a sensitive and specific marker for rhabdomyosarcoma. Appl Immunohisto-chem Mol Morphol 2005; 13: 231-236. (Pubitemid 41209015)
16. Lee J, Dedhar S, Kalluri R, Thompson E: The epithelial-mesenchymal transition: new in-sights in signaling, development, and dis-ease. J Cell Biol 2006; 172:973-981.
17. Blick T, Widodo E, Hugo H, M. W, Lenburg M, Neve R, Thompson E: Epithelial mesen-chymal transition traits in human breast cancer cell lines. Clin Exp Metastasis 2008; 25: 629-642.
18. Carcangiu M, Steeper T, Zampi G, Rosai J: Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol 1985; 83: 135-158. (Pubitemid 15128839)
19. Choi YL, Kim MK, Suh JW, Han J, Kim JH, Yang JH, Nam SJ: Immunoexpression of hbme-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci 2005; 20: 853-859. (Pubitemid 41587245)
20. Husmark J, Heldin NE, Nilsson M: N-cad-herin-mediated adhesion and aberrant catenin expression in anaplastic thyroid-car-cinoma cell lines. Int J Cancer 1999; 83:692-699. (Pubitemid 29508052)
21. Garcia-Rostan G, Camp R, Herrero A, Car-cangiu M, Rimm D, Tallini G: Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prog-nosis. Am J Pathol 2001; 158:987-996. (Pubitemid 32221790)
22. Garcia-Rostan G, Tallini G, Herrero A, DAquila T, Carcangiu M, Rimm D: Frequent mutation and nuclear localization of ß-catenin in anaplastic thyroid carcinoma. Cancer Res 1999; 59: 1811-1815. (Pubitemid 29186147)
23. Thiery J: Epithelial-mesenchymal transi-tions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
24. Thompson E, Newgreen D, Tarin D: Car-cinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005; 65:5991-5995. (Pubitemid 40994377)
25. Koo JS, Hong S, Park CS: Diffuse sclerosing variant is a major subtype of papillary thy-roid carcinoma in the young. Thyroid 2009; 19: 1225-1231.
26. Koo JS, Shin E, Hong SW: Immunohisto-chemical characteristics of diffuse sclerosing variant of papillary carcinoma: compari-son with conventional papillary carcinoma. APMIS 2010; 118:744-752.
27. Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, Pestell RG, Sotgia F, Rui H, Lisanti MP: Stromal caveo-lin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther 2009; 8:1071-1079.
28. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fi-broblasts present in invasive human breast carcinomas promote tumor growth and an-giogenesis through elevated sdf-1/cxcl12 se-cretion. Cell 2005; 121:335-348. (Pubitemid 40692295)
29. -/- null mammary stromal fibroblasts share characteristics with human breast can-cer-associated fibroblasts. Am J Pathol 2009; 174:746-761.
30. Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bos-co E, Aronow B, Witkiewicz A, Pestell RG, Knudsen ES, Lisanti MP: Human breast can-cer-associated fibroblasts (CAFs) show ca-veolin-1 downregulation and RB tumor sup-pressor functional inactivation: implications for the response to hormonal therapy. Can-cer Biol Ther 2008; 7: 1212-1225.
31. Barth K, Reh J, Sturrock A, Kasper M: Epi-thelial vs myofibroblast differentiation in immortal rat lung cell lines - modulating ef-fects of bleomycin. Histochem Cell Biol 2005; 124:453-464. (Pubitemid 41661361)
32. Gabbiani G, Ryan G, Majne G: Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971; 27: 549-550.
33. Sappino AP, Skalli O, Jackson B, Schurch W, Gabbiani G: Smooth-muscle differentiation in stromal cells of malignant and non-malig-nant breast tissues. Int J Cancer 1988; 41:707-712.
34. Cardone A, Tolino A, Zarcone R, Borruto Caracciolo G, Tartaglia E: Prognostic value of desmoplastic reaction and lymphocytic infiltration in the management of breast can-cer. Panminerva Med 1997; 39:174-177. (Pubitemid 127520544)
35. Kellermann MG, Sobral LM, da Silva SD, Zecchin KG, Graner E, Lopes MA, Kowalski LP, Coletta RD: Mutual paracrine effects of oral squamous cell carcinoma cells and nor-mal oral fibroblasts: induction of fibroblast to myofibroblast transdifferentiation and modulation of tumor cell proliferation. Oral Oncol 2008; 44: 509-517. (Pubitemid 351608623)
36. Maeshima AM, Niki T, Maeshima A, Yama-da T, Kondo H, Matsuno Y: Modified scar grade: a prognostic indicator in small pe-ripheral lung adenocarcinoma. Cancer 2002; 95:2546-2554. (Pubitemid 35424041)
37. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, Alison MR, Wright NA: Bone marrow contribution to tumor-associated myofibroblasts and fibro-blasts. Cancer Res 2004; 64: 8492-8495. (Pubitemid 39552057)
38. Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW, Banerjee D: Carcinoma-associated fibroblast-like dif-ferentiation of human mesenchymal stem cells. Cancer Res 2008; 68:4331-4339.
39. Radisky DC, Kenny PA, Bissell MJ: Fibrosis and cancer: do myofibroblasts come also from epithelial cells via emt? J Cell Biochem 2007; 101: 830-839. (Pubitemid 47040865)
40. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissell MJ: The origin of the myofibro-blasts in breast cancer. Recapitulation of tu-mor environment in culture unravels diver-sity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995; 95: 859-873.
41. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R: Discovery of endothelial to mes-enchymal transition as a source for carcino-ma-associated fibroblasts. Cancer Res 2007; 67:10123-10128. (Pubitemid 350070783)